JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

Search

Crinetics Pharmaceuticals Inc

Abrir

SetorSaúde

40.17 -0.94

Visão Geral

Variação de preço das ações

24h

Atual

Mín

39.79

Máximo

41.05

Indicadores-chave

By Trading Economics

Rendimento

-19M

-116M

Vendas

670K

1M

Margem de lucro

-11,216.004

Funcionários

437

EBITDA

-19M

-129M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+99.36% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.4B

4B

Abertura anterior

41.11

Fecho anterior

40.17

Sentimento de Notícias

By Acuity

50%

50%

168 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

22 de out. de 2025, 22:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22 de out. de 2025, 22:13 UTC

Aquisições, Fusões, Aquisições de Empresas

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22 de out. de 2025, 21:20 UTC

Ganhos

Correction to IBM 3Q Sales Jump Article

22 de out. de 2025, 20:57 UTC

Ganhos

SAP Posts Higher 3Q Revenue, Operating Profit

22 de out. de 2025, 23:46 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 de out. de 2025, 23:46 UTC

Conversa de Mercado

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22 de out. de 2025, 23:41 UTC

Conversa de Mercado

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 de out. de 2025, 23:38 UTC

Conversa de Mercado

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 de out. de 2025, 23:15 UTC

Ganhos

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22 de out. de 2025, 22:28 UTC

Conversa de Mercado

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22 de out. de 2025, 22:02 UTC

Ganhos

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22 de out. de 2025, 21:59 UTC

Aquisições, Fusões, Aquisições de Empresas

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22 de out. de 2025, 21:58 UTC

Aquisições, Fusões, Aquisições de Empresas

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22 de out. de 2025, 21:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22 de out. de 2025, 21:56 UTC

Aquisições, Fusões, Aquisições de Empresas

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22 de out. de 2025, 21:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22 de out. de 2025, 21:47 UTC

Ganhos

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 de out. de 2025, 21:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22 de out. de 2025, 21:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22 de out. de 2025, 21:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22 de out. de 2025, 21:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22 de out. de 2025, 21:28 UTC

Conversa de Mercado
Ganhos

Correction to Alcoa Tariff Market Talk

22 de out. de 2025, 21:25 UTC

Ganhos

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22 de out. de 2025, 21:17 UTC

Ganhos

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22 de out. de 2025, 21:09 UTC

Conversa de Mercado
Ganhos

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22 de out. de 2025, 21:00 UTC

Conversa de Mercado

ESG Roundup: Market Talk

22 de out. de 2025, 20:59 UTC

Ganhos

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 de out. de 2025, 20:51 UTC

Ganhos

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

22 de out. de 2025, 20:44 UTC

Ganhos

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Comparação entre Pares

Variação de preço

Crinetics Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

99.36% parte superior

Previsão para 12 meses

Média 80.6 USD  99.36%

Máximo 143 USD

Mínimo 40 USD

Com base em 16 analistas de Wall Street que oferecem metas de preço de 12 meses para Crinetics Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

16 ratings

15

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

30.39 / 33.46Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Neutral Evidence

Sentimento

By Acuity

168 / 371 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat